CompletedNot Applicable

New Biomarker for Alzheimer's Disease Diagnostic

France1,067 participantsStarted 2010-09-03

Plain-language summary

The aim of this study is to examine the relationship between plasma putative biomarkers for Alzheimer's disease (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) and : * the risk of conversion of individuals with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD), * the Alzheimer's disease progression rate.

Who can participate

Age range45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. cognitive complaint from the patient, family, or both,
✓. report by the subject or reporter of a decline in cognitive or functional performance, relative to previous abilities,
✓. cognitive disorders evidenced by clinical evaluation: impairment in memory or another cognitive domain,
✓. cognitive impairment without any repercussion on daily life, even if the subject reports difficulties concerning complex daily activities,
✓. no dementia

What they're measuring

Mean concentration of plasma AB peptides

Timeframe: at t0 and 24 months

plasma levels of Tau protein

Timeframe: t0

Trial details

NCT IDNCT01315639

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-02-26

View on ClinicalTrials.gov More Alzheimer's Disease trials